Chronic rhinosinusitis (CRS) is a chronic inflammatory disease affecting the mucosa of the paranasal sinuses, with a duration of more than 12 weeks.
Its prevalence in Western countries reaches 11%–12% and is often associated with lower respiratory tract diseases such as asthma and chronic obstructive pulmonary disease (COPD), making it a significant public health issue.
Chronic rhinosinusitis is classified into two main types: chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP). There are notable differences between CRSsNP and CRSwNP in terms of immunopathological characteristics, treatment approaches, and prognosis.
To be continued